

LANSLOWNE  
& COMPANY

advised



on the investment in Avidity Biosciences



Lansdowne & Company conducted the commercial due diligence for Riyadh Valley Company, the investment vehicle of King Saudi University, for the successful investment in Avidity

Avidity Biosciences is a privately held biotech company pioneering a new class of precision medicines – Antibody-siRNA Conjugates (ASC™) – which combine the strengths of monoclonal antibodies and siRNA-based therapeutics to overcome barriers to the delivery of siRNA and target genetic drivers of disease.

Source: Avidity Biosciences